1. S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Busse, WW; Muñoz, X; Casale, TB; Paggiaro, P; Castro, M; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S128 Baseline characteristics of patients with asthma treated with dupilumab in a real-world setting: results from the RAPID registry. (11th November 2022) Authors: Lugogo, NL; Soler, X; Menzies-Gow, A; Peters, AT; Cote, A; Hilberg, O; Xia, C; Rimington, T; Zhang, Y; de Prado Gomez, L; Rowe, PJ; Radwan, A; Jacob-Nara, JA; Deniz, Y Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study. (11th November 2022) Authors: Maspero, JF; Antila, MA; Jean, N; Deschildre, A; Bacharier, LB; Altincatal, A; Rimington, T; Laws, E; Akinlade, B; Radwan, A; Jacob-Nara, JA; Deniz, Y; Rowe, PJ; Lederer, DJ; Hardin, M Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S127 Relation between change in type 2 biomarker levels and efficacy outcomes in patients with asthma treated with dupilumab. (11th November 2022) Authors: Pavord, ID; Deniz, Y; Casale, T; Corren, J; FitzGerald, JM; Altincatal, A; Gall, R; Pandit-Abid, N; Radwan, A; Jacob-Nara, JA; Rowe, PJ; Busse, WW Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S49 Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Paggiaro, P; Castro, M; Canonica, WG; Douglass, JA; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗